Research programme: RNA interference-based therapeutics - Marina Biotech/Pfizer

Drug Profile

Research programme: RNA interference-based therapeutics - Marina Biotech/Pfizer

Latest Information Update: 03 Mar 2015

Price : $50

At a glance

  • Originator MDRNA; Pfizer
  • Developer Marina Biotech; Pfizer
  • Class Oligonucleotides; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 25 Feb 2015 Marina Biotech has patent protection for DiLA2 technology in USA, Europe, Japan, China and Australia
  • 29 Aug 2013 Early research is ongoing in USA
  • 22 Jul 2010 MDRNA has merged with Cequent Pharmaceuticals forming Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top